These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21253747)

  • 1. [Cytoprotective and antiangiogenic effects of the multikinase inhibitor sorafenib on human retinal pigmentepithelium].
    Kernt M; Thiele S; Hirneiss C; Neubauer AS; Lackerbauer CA; Wolf A; Eibl KH; Haritoglou C; Ulbig MW; Kampik A
    Ophthalmologe; 2011 May; 108(5):445-51. PubMed ID: 21253747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2.
    Kernt M; Thiele S; Neubauer AS; Koenig S; Hirneiss C; Haritoglou C; Ulbig MW; Kampik A
    Retina; 2012 Sep; 32(8):1652-63. PubMed ID: 22466477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PlGF.
    Kernt M; Neubauer AS; Liegl RG; Hirneiss C; Alge CS; Wolf A; Ulbig MW; Kampik A
    Br J Ophthalmol; 2010 Nov; 94(11):1533-9. PubMed ID: 20962354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib protects human optic nerve head astrocytes from light-induced overexpression of vascular endothelial growth factor, platelet-derived growth factor, and placenta growth factor.
    Kernt M; Liegl RG; Rueping J; Neubauer AS; Haritoglou C; Lackerbauer CA; Eibl KH; Ulbig MW; Kampik A
    Growth Factors; 2010 Jun; 28(3):211-20. PubMed ID: 20166888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Multikinase inhibitors as a new approach in neovascular age-related macular degeneration (AMD) treatment: in vitro safety evaluations of axitinib, pazopanib and sorafenib for intraocular use].
    Thiele S; Liegl RG; König S; Siedlecki J; Langer J; Eibl K; Haritoglou C; Kampik A; Kernt M
    Klin Monbl Augenheilkd; 2013 Mar; 230(3):247-54. PubMed ID: 23508753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.
    Moreno-Vinasco L; Gomberg-Maitland M; Maitland ML; Desai AA; Singleton PA; Sammani S; Sam L; Liu Y; Husain AN; Lang RM; Ratain MJ; Lussier YA; Garcia JG
    Physiol Genomics; 2008 Apr; 33(2):278-91. PubMed ID: 18303084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of ADAM10 and ADAM17 by Sorafenib Inhibits Epithelial-to-Mesenchymal Transition in Epstein-Barr Virus-Infected Retinal Pigment Epithelial Cells.
    Park GB; Kim D; Kim YS; Kim JW; Sun H; Roh KH; Yang JW; Hur DY
    Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5162-73. PubMed ID: 26244291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.
    Allen E; Walters IB; Hanahan D
    Clin Cancer Res; 2011 Aug; 17(16):5299-310. PubMed ID: 21622725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.
    Kim S; Yazici YD; Calzada G; Wang ZY; Younes MN; Jasser SA; El-Naggar AK; Myers JN
    Mol Cancer Ther; 2007 Jun; 6(6):1785-92. PubMed ID: 17575107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.
    Wilhelm SM; Adnane L; Newell P; Villanueva A; Llovet JM; Lynch M
    Mol Cancer Ther; 2008 Oct; 7(10):3129-40. PubMed ID: 18852116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.
    Kumar R; Crouthamel MC; Rominger DH; Gontarek RR; Tummino PJ; Levin RA; King AG
    Br J Cancer; 2009 Nov; 101(10):1717-23. PubMed ID: 19844230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor as an autocrine survival factor for retinal pigment epithelial cells under oxidative stress via the VEGF-R2/PI3K/Akt.
    Byeon SH; Lee SC; Choi SH; Lee HK; Lee JH; Chu YK; Kwon OW
    Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):1190-7. PubMed ID: 19834034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicotine increases the VEGF/PEDF ratio in retinal pigment epithelium: a possible mechanism for CNV in passive smokers with AMD.
    Pons M; Marin-Castaño ME
    Invest Ophthalmol Vis Sci; 2011 Jun; 52(6):3842-53. PubMed ID: 21330654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment effects of the multikinase inhibitor sorafenib on hepatoblastoma cell lines and xenografts in NMRI-Foxn1 nu mice.
    Eicher C; Dewerth A; Kirchner B; Warmann SW; Fuchs J; Armeanu-Ebinger S
    Liver Int; 2012 Apr; 32(4):574-81. PubMed ID: 22176637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion.
    Nowak-Sliwinska P; Weiss A; van Beijnum JR; Wong TJ; Ballini JP; Lovisa B; van den Bergh H; Griffioen AW
    J Cell Mol Med; 2012 Jul; 16(7):1553-62. PubMed ID: 21880113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxalomalate reduces expression and secretion of vascular endothelial growth factor in the retinal pigment epithelium and inhibits angiogenesis: Implications for age-related macular degeneration.
    Kim SH; Kim H; Ku HJ; Park JH; Cha H; Lee S; Lee JH; Park JW
    Redox Biol; 2016 Dec; 10():211-220. PubMed ID: 27810736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats.
    Reiberger T; Angermayr B; Schwabl P; Rohr-Udilova N; Mitterhauser M; Gangl A; Peck-Radosavljevic M
    J Hepatol; 2009 Nov; 51(5):865-73. PubMed ID: 19726100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
    Yuen JS; Sim MY; Sim HG; Chong TW; Lau WK; Cheng CW; Ong RW; Huynh H
    Int J Oncol; 2012 Aug; 41(2):712-20. PubMed ID: 22641227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to anti-VEGF-A treatment of retinal pigment epithelial cells in vitro.
    Puddu A; Sanguineti R; Traverso CE; Viviani GL; Nicolò M
    Eur J Ophthalmol; 2016 Aug; 26(5):425-30. PubMed ID: 27079208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of sorafenib on murine liver regeneration.
    Hora C; Romanque P; Dufour JF
    Hepatology; 2011 Feb; 53(2):577-86. PubMed ID: 21274878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.